Sunday, September 30, 2018

Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product

Dr Reddy#39;s Labs terminates Armis Biopharma#39;s licence for its investigational antibacterial product According to a press release issued by the Indian drug maker, as a result of the termination, Dr Reddy#39;s has regained worldwide rights to DFA-02, and is currently evaluating its options to take the programme forward.

from Moneycontrol Business News https://ift.tt/2Iutlyu
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

US stock: S&P 500 ends lower as investors weigh data, Middle East tensions

The S&P 500's streak came to an end, falling from its peak as weaker retail sales suggested caution among consumers. Despite a stron...